Global Tissue Plasminogen Activator Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Tissue Plasminogen Activator Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Tissue plasminogen activator (abbreviated tPA or PLAT) is a protein involved in the breakdown of blood clots. It is a serine protease found on endothelial cells, the cells that line the blood vessels. As an enzyme, it catalyzes the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. Human tPA has a molecular weight of ~70 kDa in the single-chain form.
Tissue Plasminogen Activator report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Tissue Plasminogen Activator market is projected to reach US$ 196.6 million in 2029, increasing from US$ 124 million in 2022, with the CAGR of 5.7% during the period of 2024 to 2029. Demand from Ischemic Stroke and Pulmonary Embolism are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Tissue Plasminogen Activator industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Tissue Plasminogen Activator key manufacturers include Bayer AG, Genentech, Sigma-Aldrich, Taj Pharmaceuticals, Zydus Cadila Healthcare and Calbiochem, etc. Bayer AG, Genentech, Sigma-Aldrich are top 3 players and held % sales share in total in 2022.
Tissue Plasminogen Activator can be divided into Tissue-type and Urokinase-type, etc. Tissue-type is the mainstream product in the market, accounting for % sales share globally in 2022.
Tissue Plasminogen Activator is widely used in various fields, such as Ischemic Stroke, Pulmonary Embolism, Myocardial Infarction and Others, etc. Ischemic Stroke provides greatest supports to the Tissue Plasminogen Activator industry development. In 2022, global % sales of Tissue Plasminogen Activator went into Ischemic Stroke filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tissue Plasminogen Activator market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Bayer AG
Genentech
Sigma-Aldrich
Taj Pharmaceuticals
Zydus Cadila Healthcare
Calbiochem
Segment by Type
Tissue-type
Urokinase-type
Ischemic Stroke
Pulmonary Embolism
Myocardial Infarction
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Tissue Plasminogen Activator market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Tissue Plasminogen Activator, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Tissue Plasminogen Activator industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Tissue Plasminogen Activator in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Tissue Plasminogen Activator introduction, etc. Tissue Plasminogen Activator Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Tissue Plasminogen Activator market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Tissue Plasminogen Activator report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Tissue Plasminogen Activator market is projected to reach US$ 196.6 million in 2029, increasing from US$ 124 million in 2022, with the CAGR of 5.7% during the period of 2024 to 2029. Demand from Ischemic Stroke and Pulmonary Embolism are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Tissue Plasminogen Activator industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Tissue Plasminogen Activator key manufacturers include Bayer AG, Genentech, Sigma-Aldrich, Taj Pharmaceuticals, Zydus Cadila Healthcare and Calbiochem, etc. Bayer AG, Genentech, Sigma-Aldrich are top 3 players and held % sales share in total in 2022.
Tissue Plasminogen Activator can be divided into Tissue-type and Urokinase-type, etc. Tissue-type is the mainstream product in the market, accounting for % sales share globally in 2022.
Tissue Plasminogen Activator is widely used in various fields, such as Ischemic Stroke, Pulmonary Embolism, Myocardial Infarction and Others, etc. Ischemic Stroke provides greatest supports to the Tissue Plasminogen Activator industry development. In 2022, global % sales of Tissue Plasminogen Activator went into Ischemic Stroke filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Tissue Plasminogen Activator market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Bayer AG
Genentech
Sigma-Aldrich
Taj Pharmaceuticals
Zydus Cadila Healthcare
Calbiochem
Segment by Type
Tissue-type
Urokinase-type
Segment by Application
Ischemic Stroke
Pulmonary Embolism
Myocardial Infarction
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Tissue Plasminogen Activator market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Tissue Plasminogen Activator, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Tissue Plasminogen Activator industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Tissue Plasminogen Activator in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Tissue Plasminogen Activator introduction, etc. Tissue Plasminogen Activator Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Tissue Plasminogen Activator market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices